Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q4 2022 call → NOWe need to answer YES or NO based on the transcript. The question asks: does management explain where the company's business is going by narrating what its counterparties are themselves doing and scaling? That is, does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to check if management speaks about counterparties' business as though it were part of its own, with real substance, and that the company is already inside that growth, and that the counterparties' trajectory is early and large relative to the company. Looking at the transcript, management discusses various partnerships and collaborations. For example, with Sanofi for Dupixent and Libtayo, with Bayer for EYLEA, with Alnylam for siRNA, with Intellia for CRISPR, with Decibel for gene therapy. But are these described as counterparties scaling their own operations that drive Regeneron's volume? The question is about the company's own coming volume being a consequence of those parties' own trajectories. In the transcript, management talks about its own pipeline, its own launches, its own commercial efforts. For instance, Marion McCourt talks about EYLEA sales, Libtayo sales, Dupixent sales, and their own market penetration. George Yancopoulos talks about their own clinical programs. They do mention collaborations, but they don't narrate the counterparties' own scaling as the driver of Regeneron's future revenue. For example, with Alnylam, they talk about initiating Phase 2 studies, but that's their own development. They don't say "Alnylam is expanding their manufacturing capacity, which will drive our sales." The counterparties are partners in development, not customers whose expansion drives Regeneron's volume. The question specifically asks about customers, partners, licensees, distributors, payers, operators, or programs the company already supplies or serves. In the transcript, the company's revenue comes from product sales (EYLEA, Dupixent, Libtayo) and collaboration revenue (sharing profits with Sanofi, Bayer, Roche).
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.